Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 40 of the 56 sources its claims cite were checked for support.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have been approved to target obesity-related heart failure with preserved ejection fraction. METHODS: We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The dual primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in the 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level. RESULTS: The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001), and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001). The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001). In the analysis of the hierarchical composite end point, semaglutide produced more wins than placebo (win ratio, 1.72; 95% CI, 1.37 to 2.15; P<0.001). The mean percentage change in the CRP level was -43.5% with semaglutide and -7.3% with placebo (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). Serious adverse events were reported in 35 participants (13.3%) in the semaglutide group and 71 (26.7%) in the placebo group. CONCLUSIONS: In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).
Overview
CoChat Summary
TL;DR
In STEP-HFpEF, once-weekly semaglutide 2.4 mg versus placebo in patients with heart failure with preserved ejection fraction and obesity improved heart failure symptoms/physical limitations, body weight, exercise function, a hierarchical composite outcome, and CRP over 52 weeks. Semaglutide also had fewer serious adverse events than placebo.
Key findings
- Dual primary end points: mean KCCQ-CSS change was 16.6 points with semaglutide vs 8.7 with placebo (estimated difference, 7.8 points; 95% CI, 4.8 to 10.9; P<0.001), and mean body weight changed by -13.3% vs -2.6% (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).
- Confirmatory secondary end points: 6-minute walk distance changed by 21.5 m vs 1.2 m (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001); hierarchical composite win ratio was 1.72 (95% CI, 1.37 to 2.15; P<0.001); CRP changed by -43.5% vs -7.3% (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001).
- Safety: serious adverse events occurred in 35 participants (13.3%) with semaglutide vs 71 (26.7%) with placebo (P<0.001), driven mainly by fewer cardiac disorder events (7 [2.7%] vs 30 [11.3%]; P<0.001); discontinuation due to any adverse event occurred in 35 vs 14 participants, predominantly gastrointestinal events.
- Exploratory: adjudicated heart failure hospitalization or urgent visit occurred in 1 semaglutide participant vs 12 placebo participants (hazard ratio, 0.08; 95% CI, 0.00 to 0.42).
Methods
- Randomized, double-blind, placebo-controlled trial at 96 sites in 13 countries; 529 participants with HFpEF, BMI ≥30, LVEF ≥45%, NYHA class II–IV, KCCQ-CSS <90, and 6-minute walk distance ≥100 m were assigned 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks plus 5-week follow-up.
- Dual primary end points were change in KCCQ-CSS and percentage change in body weight at week 52; confirmatory secondary end points included 6-minute walk distance, a hierarchical composite (death, heart failure events, KCCQ-CSS and 6-minute walk differences), and CRP.
- Efficacy was analyzed in the full analysis population using the treatment policy estimand; continuous end points used ANCOVA, the hierarchical composite used a win-ratio approach, and safety was analyzed in the as-treated safety population.
Limitations
- Stated in the paper: the number of non-White participants was low, which may limit generalizability; the trial was not adequately powered for clinical events such as heart failure hospitalizations/urgent visits; follow-up was limited to 1 year; specific glycated hemoglobin data were not collected beyond excluding diabetes; and SGLT2 inhibitor use was low.
- Evident from the text: the trial population was 95.8% White, median age 69 years, all with BMI ≥30, and patients with diabetes were excluded, so findings may not generalize to more diverse, younger, non-obese, or diabetes populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 90 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that obesity and excess adiposity are not simply coexisting conditions but may play a role in the development and progression of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Background calls obesity a risk factor for incident heart failure, and the Discussion links severe obesity to more adverse outcomes and hospitalizations among patients who already have HFPEF. These findings support the hedged suggestion that obesity may matter beyond coexistence, but the paper does not establish a role for excess adiposity specifically in the development or progression of HFPEF; its HFPEF analysis concerns BMI and outcomes. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. source
The Discussion (page not provided) states that increased adiposity promotes conditions that contribute to HFpEF pathophysiology. The Conclusions (page not provided) add that adipose deposition may have adverse consequences for HFpEF. Together, these support the citing sentence’s hedged claim that adiposity may play a role rather than merely coexist with the disease. (LLM, conf=0.88)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The main text explicitly says that excess adipose tissue likely plays a pivotal role in the development and progression of HFpEF. It also describes evidence linking adiposity to incident HFpEF and adverse outcomes in established HFpEF. This supports the citing sentence’s hedged claim that obesity and excess adiposity may contribute rather than merely coexist. (LLM, conf=0.94)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5 describes obesity-related changes that can lead to HFpEF. Section 5.8.1 links visceral adiposity to the risk of developing HFpEF and reports that central adiposity is associated with worse outcomes in patients who have it. Together, these passages support the hedged claim that excess adiposity may contribute to development and progression. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that adipose tissue may play a pivotal role in the development, progression, and adverse outcomes of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a U-shaped association between BMI and adverse outcomes in patients with HFpEF, and the paper describes obesity as a risk factor for developing heart failure generally. It does not establish a role for adipose tissue in HFpEF progression or specifically in its development; BMI is not a direct measure of adipose-tissue activity. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Partly supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says increased adiposity contributes to HFpEF pathophysiology and links abdominal fat to impaired exercise tolerance in older obese patients. This supports a possible role for adipose tissue, but the paper does not establish its role in HFpEF progression or in adverse clinical outcomes. (LLM, conf=0.85)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The paper’s main text explicitly says that excess adipose tissue likely plays a pivotal role in HFpEF development, progression, and adverse outcomes. It also identifies visceral adipose tissue as especially important in metabolic/obese HFpEF. (LLM, conf=0.95)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5.8.1 (page not provided) describes a pivotal role for visceral adipose tissue in obese HFpEF, linking it to both incident HFpEF risk and worse outcomes. Section 5.3 (page not provided) describes mechanisms by which epicardial adipose tissue may impair cardiac function and reports associations with greater disease severity and hospitalization or death. Together, these passages support the claim’s hedged wording. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Even when patients have well compensated heart failure with preserved ejection fraction and are in stable condition, they have markedly impaired objectively measured physical function. 34”
What the sources say
- Partly supportedcites [34] 34. Pandey A, Shah SJ, Butler J, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol 2021; 78: 1166-87. sourceExperimental — accuracy not yet measured
In ‘EI: A Key Manifestation of HFpEF’ (page unavailable), the review reports that objectively measured peak oxygen uptake is, on average, 35% lower in patients with HFpEF than in matched healthy controls. This supports marked impairment, but the passage does not establish that the patients were well-compensated and clinically stable. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our findings of substantial reductions in symptoms and physical limitations and improvements in exercise function that parallel a greater degree of weight loss with semaglutide than with placebo may offer insights into the long-standing controversy surrounding weight (and weight loss) in persons with heart failure. 8”
What the sources say
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“previous global clinical trial programs of agents such as SGLT2 inhibitors, sacubitrilvalsartan, and spironolactone for heart failure with preserved ejection fraction showed only modest changes in KCCQ scores (ranging from 0.5 to 2.3 points). 31-33”
What the sources say
- Partly supportedcites [31] 31. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation 2022; 145: 184-93. sourceExperimental — accuracy not yet measured
The Discussion (page not available) reports modest KCCQ improvements in the TOPCAT spironolactone and PARAGON-HF sacubitril/valsartan trials, while the Results report modest improvements with the SGLT2 inhibitor empagliflozin. These passages support the overall characterization, but they do not establish the stated range of 0.5 to 2.3 points. (LLM, conf=0.86)
- Partly supportedcites [32] 32. Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of dapagliflozin on health status inpatients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol 2023; 81: 460-73. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes the KCCQ benefit with dapagliflozin in DELIVER as modestly higher than that with empagliflozin in EMPEROR-PRESERVED, and mentions the sacubitril-valsartan PARAGON-HF trial. It does not establish the claimed 0.5–2.3-point range across those trials or report a corresponding spironolactone result. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [33] 33. Lewis EF, Kim HY, Claggett B, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2016; 9(3): e001937. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
45 more claims · 1 with their cited sources checked
Create a free account to see all 113 claims and every source verdict.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 43
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and there is evidence that semaglutide 2.4 mg improves heart failure with preserved ejection fraction in individuals without diabetes by a potentially direct or indirect effect on epicardial adipose tissue (Kosiborod et al, 2023;Myasoedova et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Kosiborod et al, 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with HFpEF and obesity (with and without diabetes), semaglutide 2.4 mg once weekly for 52 weeks improved symptoms, physical function, exercise function and bodyweight compared to placebo (STEP HFpEF and STEP HFpEF DM clinical trials) [59,91].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the STEP-HFpEF trial, semaglutide treatment in patients with obesity-related HFpEF led to significant improvements in the 6-min walk distance (6MWD) and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), despite concurrent losses in lean mass [38].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“weight-loss interventions (eg, gastric bypass surgery and glucagon-like peptide-1 receptor agonists) can reduce the risk of incident HF and improve symptoms in patients with established HFpEF.16–20”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
39 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationO'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Self-citationHeart Failure With Preserved, Borderline, and Reduced Ejection Fraction
Shah, K. S., Xu, H., Matsouaka, R. A., Bhatt, D. L., Heidenreich, P. A., Hernandez, A. F., Devore, A. D., Yancy, C. W., & Fonarow, G. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.074 · Cited by 1,110
Epidemiology of Heart Failure: A Contemporary Perspective
Roger, V. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318172 · Cited by 946
Kitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016) · JAMA · doi:10.1001/jama.2015.17346 · Cited by 921
Self-citationBordicchia, M., Liu, D., Amri, E.-Z., Ailhaud, G., Dessì-Fulgheri, P., Zhang, C., Takahashi, N., Sarzani, R., & Collins, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59701 · Cited by 872
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationEvaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Self-citation
Cited by
Items 501–600 of 1,639
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037510 · Cited by 12
“34 Similarly, the STEP-HFpEF DM (Effect of Semaglutide 2.4 mg Once-Weekly on Function and Symptoms in Subjects With Obesity-Related Heart Failure With Preserved Ejection Fraction, and Type 2 Diabetes) trial, including patients with T2D, BMI of at least 30 kg/m 2 , and LVEF of at least 45%, showed…”
InfluentialKelkar, R., Barve, N., Kelkar, R., Kharel, S., Khanapurkar, S., & Yadav, R. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1453297 · Cited by 10
Iwakura, K., Onishi, T., Okamura, A., Koyama, Y., Tanaka, N., Okada, M., Fujii, K., Seo, M., Yamada, T., Yano, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-52101-8 · Cited by 12
Unraveling Comorbidities Contribution to Cardiac Diastolic Dysfunction and Heart Failure
Villalba‐Orero, M., López-Olañeta, M. M., Campos-Olmo, B., Jiménez‐Carretero, D., Sánchez-García, L., Sánchez‐Cabo, F., Ausiello, A., Cañas-Álvaro, R., Camafeita, E., Vázquez, J., et al. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011724 · Cited by 14
“5– 7 Although these findings are encouraging, the precise impact of age and the individual influence of comorbidities in driving diastolic dysfunction leading to HFpEF remains obscure.”
Current and Future of Heart Failure Care in Asia
Yoo, S. G. K., Ahmed, M., & Sweitzer, N. K. (2024) · International Journal of Heart Failure · doi:10.36628/ijhf.2024.0033 · Cited by 14
“23) The potential of GLP-1 agonists as prevention therapy for cardiovascular disease is of intense interest, with one study demonstrating a 20% reduction in cardiovascular death, nonfatal myocardial infarction, or stroke for those with initial body-mass index >27.”
BackgroundPatel, S. M., Morrow, D. A., Bellavia, A., Berg, D. D., Bhatt, D. L., Jarolím, P., Leiter, L. A., McGuire, D. K., Raz, I., Steg, P. G., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3118 · Cited by 9
“29 As such, the putative mechanisms underlying the relationship between the NP system and obesity warrant further investigation.”
BackgroundJensen, S. B. K., Fiorenza, M., Juhl, C. R., Sandsdal, R. M., Jensen, E., Seier, S. S., Janus, C., Jørgensen, J. R., Blond, M. B., Holst, J. J., et al. (2026) · Sports Medicine · doi:10.1007/s40279-025-02386-0 · Cited by 9
Basdas, R., Martínez-Cereijo, J. M., Fernández, Á. L., Reija, L., Cabaleiro, A., Bravo, S. B., González‐Juanatey, J. R., & Eirás, S. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.03.009 · Cited by 16
Radakrishnan, A., Agrawal, S., Singh, N., Barbieri, A., Shaw, L. J., Gulati, M., & Lala, A. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100928 · Cited by 14
“…improvement in quality of life as measured by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), greater percentage of body weight loss with improvement in the 6-minute walk test and a lower likelihood of hospitalization for HF or an urgent visit at 52 weeks [168].”
Salah, H. M., Ambrosy, A. P., Biegus, J., Bocchi, E. A., Butler, J., Chioncel, O. D., Cotter, G., Davison, B. A., Dzudié, A., Freund, Y., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.09.020 · Cited by 11
Self-citationCiconte, G., Salerno, R., Fuga, A., Vuturo, A., Boccellino, A., Negro, G., Rondine, R., Ballarotto, M., Ciaccio, C., Izzo, A., et al. (2026) · EP Europace · doi:10.1093/europace/euag018 · Cited by 18
“42,43 Observational data also suggest a lower incidence and progression of AF among GLP-1RA users, indicating a potential protective electrophysiological role.”
Spertus, J. A., Jones, P. G., Butler, J., & Arnold, S. V. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102587 · Cited by 13
Self-citationMethawasin, M., Meinke, S., Radke, M. H., Farman, G. P., Hourani, Z., Smith, J. E., Guo, W., Granzier, H. L. M., & Gotthardt, M. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf171 · Cited by 9
Alhomoud, I. S., Wheeler, S. E., & Dixon, D. L. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0038 · Cited by 14
From Gut to Heart: Role of Indole-3-Propionic Acid in HFpEF
Vacca, A., & Schiattarella, G. G. (2024) · Circulation Research · doi:10.1161/circresaha.123.323947 · Cited by 8
Obesity and Cardiometabolic Disease: Insights From Genetic Studies
Dash, S. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.01.034 · Cited by 11
Madsen, P. L., Sejersen, C., Nyberg, M., Sørensen, M. H., Hellsten, Y., Gæde, P., & Bojer, A. S. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1294369 · Cited by 11
The Quest for Understanding Diabetic Cardiomyopathy
Lala, A., Mentz, R. J., & Santos‐Gallego, C. G. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.036 · Cited by 8
Pop, A. S. K., Dănilă, M. D., Giuchici, S., Buriman, D. G., Lolescu, B. M., Sturza, A., Muntean, D. M., & Lascu, A. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2024-0384 · Cited by 11
Sabina, M., & Alsamman, M. (2024) · Cardiology Research · doi:10.14740/cr1600 · Cited by 10
“We have summed up the results of each trial discussed in this analysis in Table 3 [20-29].”
BackgroundMethodMinnetti, M., Barazzoni, R., Batsis, J. A., Busetto, L., Yumuk, V., Poggiogalle, E., Weijs, P. J. M., & Donini, L. M. (2025) · Obesity Facts · doi:10.1159/000548370 · Cited by 15
“…significant weight loss, as well as cardiometabolic and renal improvements partially independent of weight loss, key factors such as nutritional adequacy, lean mass preservation, metabolic flexibility, and long-term behavioral adaptations still need to be considered and addressed [4, 5, 120].”
The expanding role of semaglutide: beyond glycemic control
Zarei, M., Sabetkasaei, M., Mozafari, M., & Zaeri, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01663-z · Cited by 11
“Adverse events, primarily gastrointestinal, were more frequent in the semaglutide group, reinforcing its dual efficacy in weight and glycemic control [ 78 ].”
Heart failure with preserved ejection fraction: New challenges and new hopes
Logeart, D. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104185 · Cited by 8
Sorimachi, H., Obokata, M., Omote, K., Reddy, Y. N. V., Burkhoff, D., Shah, S. J., & Borlaug, B. A. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.08.042 · Cited by 10
Self-citationArdehali, H. (2024) · Journal of Clinical Investigation · doi:10.1172/jci186225 · Cited by 9
“Finally, STEP-HFpEF demonstrated that treatment with sema-glutide in patients with heart failure with preserved ejection fraction is associated with a reduction in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss (24).”
MethodMesquita, T., Miguel‐dos‐Santos, R., Liu, W., Fournier, M., Rogers, R. G., Alfaro, J., Nawaz, A., Sanchez, L., Jones, X. M., Li, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56186-1 · Cited by 13
Latest pharmaceutical approaches across the spectrum of heart failure
Bismpos, D., Wintrich, J., Hoevelmann, J., & Böhm, M. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10389-8 · Cited by 11
Dorneles, G. P., Algeri, E. D. B. D. O., Lauterbach, G., Pereira, M. G., & Fernandes, B. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2303-8558 · Cited by 9
“The remaining studies presented low risk of bias for all domains of the RoB 2.0 instrument, indicating a low overall risk of bias [8–12, 25, 27, 28].”
BackgroundInfluentialDuhan, S., Kurpad, K. P., Keisham, B., Shtembari, J., Brener, A., Kanakadandi, U. B., Garg, A., Adoni, N. A., & Mehta, S. S. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133604 · Cited by 8
Zupec, J. F., Munger, R., Scaletta, A., & Quinn, D. H. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11279 · Cited by 9
Talavera, J. A., Teixeira, L., Klein, B., Lopes, R. R. D. S., Urina‐Jassir, D., Navalha, D. D. P., Bettinotti, B. G. M., Fernandez, N., Urina‐Triana, M., Welty, F. K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70102 · Cited by 11
Using Second-Generation Anti-Obesity Medications
Schmitz, S. H., & Aronne, L. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0002 · Cited by 11
Sillassen, C. D. B., Petersen, J. J., Faltermeier, P., Yucel, D., Siddiqui, F., Andersen, R. K., Graever, L., Bjerg, J. L., Kamp, C. B., Grand, J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04486-0 · Cited by 10
“Myocardial infarction was reported as an outcome in 33 trials [33, 35, 36, 39, 41–43, 45, 46, 48, 49, 51–68, 71, 72, 80, 82].”
InfluentialBeyond Blood Sugar: A Scoping Review of GLP-1 Receptor Agonists in Cardiovascular Care
Gupta, N., Zayyad, Z. A., Bhattaram, R., Tiu, D. R., Dau, J., Guburxani, V., Kalzuna, S. D., & Shroff, A. R. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00426-4 · Cited by 12
“The STEP-HFpEF trial reflected similar outcomes; semaglutide improved body weight, quality of life, and 6MWD in obese patients with heart failure with reduced ejection fraction (HFpEF) and T2DM, likely mediated through weight loss [34].”
Pharmacologic Management of Heart Failure with Preserved Ejection Fraction (HFpEF) in Older Adults
Hashemi, A., Kwak, M. J., & Goyal, P. (2025) · Drugs & Aging · doi:10.1007/s40266-024-01165-2 · Cited by 8
“Data supporting its use in HFpEF: The Semaglutide Treatment Effect in People with Obesity and HFpEF (STEP-HFpEF) RCT [108] examined adults with HFpEF and a body mass index of 30 kg/m 2 , demonstrating that semaglutide leads to significant weight reduction (10.7% more weight loss compared with…”
InfluentialObesity, cardiovascular and cerebrovascular disease: the role of GLP-1 receptor agonists
Tirandi, A., Montecucco, F., Carbone, F., & Liberale, L. (2024) · Polish Archives of Internal Medicine · doi:10.20452/pamw.16658 · Cited by 8
Managing Obesity in Heart Failure: Latest Evidence and Knowledge Gaps
Ibrahim, R., Pham, H. N., Vest, A. R., & William, P. (2024) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-024-01056-0 · Cited by 11
“The safety and efficacy of semaglutide has been subsequently evaluated in the Semaglutide Treatment Effect in People With Obesity and HFpEF (STEP-HFpEF) study, a randomized placebo-controlled clinical trial that assessed the efficacy of semaglutide in patients with obesity and HFpEF [45].”
Pharmacotherapy for older people with obesity
Boyle, L. D., Akbaş, F., Yazıcı, D., McGowan, B. M., & Yumuk, V. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.05.006 · Cited by 10
Tani, Y., Reddy, Y. N. V., Verbrugge, F. H., Yang, J. H., Negishi, K., Harada, T., Kagami, K., Saito, Y., Yuasa, N., Sorimachi, H., et al. (2024) · European Heart Journal - Imaging Methods and Practice · doi:10.1093/ehjimp/qyae059 · Cited by 8
Gul, U., Aung, T., Martin, M., Farrukh, D. N., Shah, P., Lovely, Z. S., León, E. M., Alansaari, M., Maini, S., Fariduddin, M. M., et al. (2024) · Cureus · doi:10.7759/cureus.76519 · Cited by 16
Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary?
Chavez, A. M., Barria, R. C., & León-Sanz, M. (2025) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001130 · Cited by 30
“[16].”
Steenackers, N., Toumassian, J., Deleus, E., Mertens, A. C., Lannoo, M., Pazmiño, S., van Laar, A. D. E., der Schueren, B. V., & Vangoitsenhoven, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1569468 · Cited by 21
“In contrast, GLP-1 agonists demonstrated protective cardiovascular effects (86 – 89).”
Ostrominski, J. W., Wagholikar, K. B., Olsson, K., Ünlü, O., Zelle, D., Kumar, S., Smith, A. M., Toliver, J. C., Michalak, W., Fabricatore, A. N., et al. (2024) · Obesity · doi:10.1002/oby.24186 · Cited by 8
Saeed, A., Mulukutla, S. R., Thoma, F. W., Lemon, L. S., Koczo, A., Reís, S. E., Marroquin, O. C., & Kip, K. E. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-00775 · Cited by 10
Opp, D. N., Jain, C. C., Egbe, A. C., Borlaug, B. A., Reddy, Y. N. V., Connolly, H. M., Lara-Breitinger, K. M., Cordina, R., & Miranda, W. R. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae314 · Cited by 8
Self-citationXie, Y., Choi, T., & Al-Aly, Z. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002150 · Cited by 8
le Roux, C. W., Wharton, S., Bozkurt, B., Platz, E., Bleckert, G., Hussain, S. A., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70196 · Cited by 9
Fopiano, K. A., Zhazykbayeva, S., El‐Battrawy, I., Buncha, V., Pearson, W. M., Hardell, D. J., Lang, L., Hamdani, N., & Bagi, Z. A. (2024) · Microcirculation · doi:10.1111/micc.12888 · Cited by 8
Distinct Profiles and New Pharmacological Targets for Heart Failure with Preserved Ejection Fraction
Palazzuoli, A., Severino, P., D’Amato, A., Myftari, V., Tricarico, L., Correale, M., Dattilo, G., Fioretti, F., & Nodari, S. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2507270 · Cited by 10
“[146–150]).”
BackgroundAdvances in the management of obesity and heart failure: latest evidence from clinical trials
Costa, T. A., & Harrington, J. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001214 · Cited by 7
“KEY POINTS (cid:1) Individuals with heart failure with preserved ejection and increased risk for heart failure hospitalization (cid:1) Antiobesity medications such as for persons with obesity-related HFpEF.”
Wang, P., Zhao, Y., Wang, D., Wang, B., Liu, H., Fu, G., Tao, L., & Tian, G. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15029 · Cited by 8
“39 In fact, due to the relatively short follow-up period (1 year), the literature did not yet have suf fi cient data to ascertain comparable mortality events.”
Zhao, S., Liu, H., & Liu, A. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04910-6 · Cited by 12
“Over the past decades, several treatments have been introduced to prevent heart and kidney impairment in individuals with and without T2D [21–23].”
Multiomics Insight Into the Role of Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure
Tao, Y., Liu, Q., Wang, Y., Gong, Y., Xu, M., Jiang, R., & Zhang, K. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15310 · Cited by 7
Hullon, D., Janiec, K., Florova, V., Trach, A., Volkova, Y., & Mnevets, R. O. (2025) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000344 · Cited by 8
Costa, T. A., Felix, N. S., Chagas, G. C. L., Terán, S., Boslough, M., Shelar, V., Lee, M. M. Y., Pandey, A., Abreu, M., McGuire, D. K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16512 · Cited by 7
Dobbie, L. J., Tolvanen, L., Alves, D., Baker, J. L., Bez, N. S., Birney, S., Bogl, L. H., Brown, A., Bullo, M., Clare, K., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00122-1 · Cited by 8
Correale, M., Salzano, A., Tricarico, L., Cittadini, A., Crisci, G., Dattilo, G., Inciardi, R. M., Fiori, E., Paolillo, S., Ruocco, G. M., et al. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.106457 · Cited by 9
Integrating Senescence and Oxidative Stress in Cardiac Disease
Yun, H. R., Singh, M. K., Han, S., Ranbhise, J. S., Ha, J., Kim, S. S., & Kang, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411917 · Cited by 8
Wang, T., Pate, V., Wyss, R., Buse, J. B., Kosorok, M. R., & Stürmer, T. (2024) · American Journal of Epidemiology · doi:10.1093/aje/kwae322 · Cited by 10
Corrao, S., Falcone, F., Mirarchi, L., Amodeo, S., & Calvo, L. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01761-4 · Cited by 13
Clinical Outcomes of Metabolic Surgery on Diuretic Use in Patients With Heart Failure
Kachmar, M., Corpodean, F., LaChute, C., Popiv, I., Cook, M. W., Danos, D., Albaugh, V. L., Moraes, D. L., Tang, W. H. W., & Schauer, P. R. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.07.012 · Cited by 8
Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes
Cohen, C., Cohen, R., & Sabouret, P. F. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2406233 · Cited by 8
Semaglutide attenuates lipotoxicity-induced cardiac injury by inhibiting Slc27a2 expression
Pan, X., Wang, S., Yang, X., Jia, B., & Chen, S. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111583 · Cited by 7
Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
Gudzune, K. A., Apovian, C. M., Aroda, V. R., Aronne, L. J., Balapattabi, K., Bennett, A. K., ChallaSivaKanaka, S., ElSayed, N. A., Fitch, A., Fitzpatrick, S. L., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0008 · Cited by 27
Ruseva, A., Michalak, W., Fabricatore, A. N., Hartaigh, B. Ó., Zhao, Z., & Umashanker, D. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03320-6 · Cited by 13
“…pre-served ejection fraction (STEP-HFpEF), patients treated with semaglutide 2.4 mg had mean percentage reduction in body weight of 13.3% and experienced significant improvements in heart failure-related symptoms, walking distance, and blood pressure measurements from baseline to 52 weeks [15].”
InfluentialAdvanced chronic kidney disease coexisting with heart failure: navigating patients’ management
Zoccali, C., Levin, A., Mallamaci, F., Giugliano, R. P., & Caterina, R. D. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf128 · Cited by 12
“The selection of specific GLP-1 RAs with proven cardiovascular benefits ( e.g. semaglutide, tirzepatide) is recommended given the high risk of cardiovascular events in patients with CKD and HF [55 , 56 ].”
Troshina, E. A., Antsiferov, M. B., As, A., Galstyan, G. R., Маркова, Т. Н., Romantsova, T. I., Mazurina, N. V., & Koteshkova, O. M. K. (2025) · Problems of Endocrinology · doi:10.14341/probl13677 · Cited by 14
Kato, E. T., Lewis, B. S., & Ono, K. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad072 · Cited by 8
Modulating the Secretome of Fat to Treat Heart Failure
Salyer, L. G., Wang, Y., Ma, X., Foryst‐Ludwig, A., Kintscher, U., Chennappan, S., Kontaridis, M. I., & McKinsey, T. A. (2025) · Circulation Research · doi:10.1161/circresaha.125.325593 · Cited by 8
Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction
Lassen, M. C. H., Ostrominski, J. W., Claggett, B. L., Neuen, B. L., Beldhuis, I. E., Butt, J. H., Biering‐Sørensen, T., Desai, A. S., Lewis, E. F., Jhund, P. S., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.03.042 · Cited by 11
Guo, F.-S., Guo, C., Dou, J., Wang, J.-X., Wu, R., Song, S., Sun, X.-L., Hu, Y., & Wei, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1430277 · Cited by 7
“For HF patients, weight control should be carried out along with cardiac rehabilitation to improve the long-term survival rate (47 – 49).”
Zhang, J., Guan, X., Kong, M.-W., Xia, M., Yu, Y., & Zhang, C. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156433 · Cited by 9
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
Sheth, S., Merola, J. F., Weber, B. N., Prussick, R. B., Yeung, J., Liu, C., Glick, B. P., Reddy, S. M., Cook-Bolden, F. E., Wallace, E. B., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.0859 · Cited by 17
Kim, M.-K., & Kim, H. S. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.228 · Cited by 10
Hong, B., Kim, H., Lee, D., & Kim, K. (2025) · Pharmaceuticals · doi:10.3390/ph18071058 · Cited by 11
“In total, 10 studies were included in the final meta-analysis: STEP 1 [12], STEP 2 [15], STEP 3 [21], STEP 5 [20], STEP 6 [22], STEP 6 post hoc [23], STEP 7 [24], STEP 8 [25], STEP-HFpEF [26], and STEP-HFpEF DM [27].”
McIntyre, R. S. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20241087 · Cited by 12
Labbé, E.-A., Thibodeau, S.-È., Walsh‐Wilkinson, É., Chalifour, M., Sirois, P.-O., Leblanc, J., Morin-Grandmont, A., Arsenault, M., & Couët, J. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00092.2025 · Cited by 7
Meyer, M., Núñez, J. E., Goyal, P., Silverman, D. N., van Berlo, J. H., & Maharaj, V. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2024.22 · Cited by 8
“A first glimpse of the tremendous potential of GLP-1 agonists was provided in the STEP-HFpEF trial that demonstrated a marked improvement in quality of life and reductions in clinical events [54] .”
Self-citationNeff, G. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70148 · Cited by 13
“129,130 Furthermore Furthermore, in people with T2D and chronic kidney disease in the FLOW trial, semaglutide significantly reduced kidney failure, decline in estimated glomerular filtration rate, and death from cardio-kidney causes.”
Horiuchi, Y., Wettersten, N. W., Asami, M., Yahagi, K., Komiyama, K., Yuzawa, H., Tanaka, J., Aoki, J., & Tanabe, K. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132611 · Cited by 8
Impact of Incretin-Based Therapy on Skeletal Muscle Health
Koceva, A., Janež, A., & Jensterle, M. (2025) · Medicina · doi:10.3390/medicina61091691 · Cited by 16
“In obesity with heart failure with preserved ejection fraction, semaglutide 2.4 mg weekly over 52 weeks improved both the 6-min walk test by 21.5 m and self-reported physical function [63].”
InfluentialOld and new anti-obesity drugs
Dodangeh, S., & Hasani‐Ranjbar, S. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01512-5 · Cited by 8
Nagpal, S., & Gibson, G. C. (2024) · medRxiv · doi:10.1101/2024.07.29.24311065 · Cited by 7
Cardiovascular effects of anti-obesity medications: the perils and promise
Zheng, H. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000114 · Cited by 7
Mochel, J. P., Ward, J. L., Blondel, T., Kundu, D., Merodio, M. M., Zemirline, C., Guillot, E., Giebelhaus, R. T., de la Mata, A. P., Iennarella‐Servantez, C. A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-71202-y · Cited by 11
Kittleson, M. D., Panjrath, G. S., Bates, K., Breathett, K. K., Dixon, D. L., Januzzi, J. L., & Mohammed, S. F. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.06.018 · Cited by 25
Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure
Llongueras-Espí, P., García‐Romero, E., Colet, J. C., & González‐Costello, J. (2025) · Biomolecules · doi:10.3390/biom15091342 · Cited by 11
“Secondary endpoints included a hierarchical composite outcome encompassing heart failure events [64].”
Patel, R., Kokori, E., Olatunji, G. D., Adejumo, F. A., Ukah, J. D., Babalola, A. E., Ndakotsu, A., Abraham, I. C., & Aderinto, N. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00704-1 · Cited by 10
“Hemodynamic alterations are central to the pathophysiology of HFpEF in obese individuals [13].”
An Updated Prioritization of Geroscience- Guided FDA-Approved Drugs Repurposed to Target Aging
Leone, M., & Barzilai, N. (2024) · Medical Research Archives · doi:10.18103/mra.v12i2.5138 · Cited by 12
Mao, T., Chen, J., Su, T., Xie, L., Qu, X., Feng, R., Pan, Y., Wan, J., Cui, X., Jia, W., et al. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01448-z · Cited by 11
Chiang, C., Wang, K.-L., Cheng, H., Chao, T., & Sung, S. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001263 · Cited by 12
Jia, I.-I.-T. T., Bloomfield, G. C., Chen, M. Y., Cunningham, M. H., Azagury, D. E., Alimi, Y., & Prindeze, N. J. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-12086-5 · Cited by 13
Lian, L., Huang, C., Chen, Q., & Zhou, X. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i2.103845 · Cited by 13
Krishnan, S., Srivastava, P. K., Attaluri, J., Nayeri, R., Chatterjee, D., Patel, J., Nsair, A., Budoff, M. J., & Nayeri, A. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12010019 · Cited by 13
Wu, R., Xing, B., Zhou, Z., Yu, L., & Wang, H. (2025) · European journal of medical research · doi:10.1186/s40001-025-03124-y · Cited by 9
“However, no significant effects were observed for other CV outcomes, including angina unstable (RR 0.87, 95% CI 0.72– 1.06; I 2 0%, 4 studies [15, 19–21]), coronary artery disease (RR 0.76, 95% CI 0.57–1.01; I 2 0%, 4 studies [15, 18–20]), cardiac failure congestive (RR 0.80, 95% CI 0.50–1.28; I 2…”
InfluentialKambič, T., Lavie, C. J., & Eijsvogels, T. M. H. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad856 · Cited by 7
“1,2,4 Additional aerobic training can also attenuate gastrointestinal symptoms that are often induced by semaglutide, 9 beyond the typical improvements of physical performance.”
BackgroundSleeve gastrectomy as a bridge to cardiac recovery - A retrospective comparative cohort study
Goubar, T., Kim, S., Cistulli, D., Fenton‐Lee, D., Rushworth, R. L., Macdonald, P. S., & KEOGH, A. M. (2025) · JHLT Open · doi:10.1016/j.jhlto.2025.100224 · Cited by 6
“49 This suggests that in the setting of advanced heart failure, the safety and efficacy of treatment with GLP-1 agonists is as yet unresolved and may not obviate the need for bariatric surgery in affected patients.”
Natali, L. D., de Oliveira, L. G. M. S., Barbosa, I. C. D. Q., & Portilho, N. D. P. (2025) · Heart & Lung · doi:10.1016/j.hrtlng.2025.07.009 · Cited by 7
GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies
Palani, A., Patel, S., Patel, S., Srivastava, S., Patel, J., Salehin, S., Birnbaum, Y., & Allencherril, J. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07744-8 · Cited by 8
“Those in the treatment group also had greater improvements in exercise function and greater weight loss than placebo [19].”
Harnessing Evolution and Biomimetics to Enhance Planetary Health: Kidney Insights
Stenvinkel, P., Shiels, P. G., Kotanko, P., Evenepoel, P., & Johnson, R. J. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000582 · Cited by 7
“These nature-based drugs treat not only type 2 diabetes but are also used to treat obesity 66 ; slow progression of CKD 67 ; improve heart failure 68 ; and possibly decrease addictive behavior, such as smoking 69 and alcoholism.”
Metadata
- Authors
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., Melenovsky, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., Van der Meer, P., von Lewinski, D., Wolf, D., & Petrie, M. C.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) — both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Diabetes Research Centre, University of Leicester, and National Institute for Health and Care Research Leicester Biomedical Research Centre (M.D.), Leicester, the Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (F.Z.A.), and the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.) — all in the United Kingdom; the Department of Cardiovascular Medicine ...
- ORCID
- Kosiborod, Mikhail N.
- Borlaug, Barry A.
- Butler, Javed
- Davies, Melanie
- Hovingh, G. Kees
- Kitzman, Dalane W.
- Shah, Sanjiv J.
- Verma, Subodh
- Abhayaratna, Walter
- Ahmed, Fozia Z.
- Chopra, Vijay
- Ezekowitz, Justin
- Fu, Michael
- Ito, Hiroshi
- Lelonek, Małgorzata
- Merkely, Bela
- Núñez, Julio
- Perna, Eduardo
- Schou, Morten
- Senni, Michele
- Sharma, Kavita
- Wolf, Dennis
- Petrie, Mark C
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-21
- Volume
- 389
- Issue
- 12
- Pages
- 1069-1084
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4386154055
- Cited by
- 1,669
- References
- 41
- Citations by year
- 2026: 548 · 2025: 597 · 2024: 461 · 2023: 61
- FWCI
- 327.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, heart failure with preserved ejection fraction, obesity, weight loss, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, GLP-1 receptor agonists, heart failure events, body weight, symptom burden
- MeSH terms
- Semaglutide, Glucagon-Like Peptides, Heart Failure, Humans, Obesity, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.